<DOC>
	<DOCNO>NCT02365948</DOCNO>
	<brief_summary>This study characterize pharmacokinetics ( PK ) certolizumab pegol ( CZP ) evaluate safety CZP healthy Chinese subject . 36 subject randomize receive one 3 dose level CZP placebo . The total study duration approximately 71-94 day subject .</brief_summary>
	<brief_title>A Study Certolizumab Pegol Evaluate Pharmacokinetics Safety Adult Healthy Chinese Subjects</brief_title>
	<detailed_description>This Phase 1 , randomize , double-blind , placebo-controlled , single-center , single escalate dose study healthy Chinese subject . The primary objective study characterize pharmacokinetics ( PK ) certolizumab pegol ( CZP ) healthy Chinese subject single subcutaneous ( sc ) dose . The secondary objective evaluate safety CZP healthy Chinese subject single sc dose . 36 healthy Chinese subject ( 18 male 18 female ) randomize receive one 3 dose level CZP ( 100 mg , 200 mg 400 mg ) placebo give sc injection . Each dose group begin treatment stagger minimum 14 day . The total duration study approximately 71 94 day subject . This include 2 21 day Screening Period , 1 day treatment 70 day Observation Period administration single dose investigational medicinal product .</detailed_description>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>An Institutional Review Board ( IRB ) / Independent Ethics Committee ( IEC ) approve write Informed Consent Form ( ICF ) sign date subject Subject consider reliable capable adhere protocol ( eg , able understand complete diary ) , visit schedule medication intake accord judgment investigator Subject male female 18 45 year age , inclusive Results clinical laboratory test within reference range laboratory outside reference range laboratory consider nonclinically significant investigator . This allowed aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) bilirubin value upper limit normal ( ULN ) range Have body weight 50 80 kg body mass index ( BMI ) 19 24 kg/m^2 In good health determine investigator basis medical history , physical examination , vital sign , 12lead electrocardiogram ( ECG ) result laboratory test Pretreatment Period ( Screening Baseline ) Nonsmoker former smoker give smoke 6 month first administration Willing abstain alcohol , tobacco caffeinecontaining product 48 hour prior admission clinic entire inclinic stay Subjects register permanent Citizen People 's Republic China Chinese evidence 4 grandparent Chinese ethnical definition Female subject childbearing potential negative pregnancy test Screening Baseline ( Day 1 ) use medically accept method contraception ( one barrier method include another ie , hormonal contraception least 2 cycle , intrauterine device , implant device , diaphragm spermicide , monogamous relationship vasectomize [ least 3 month ] partner use condom spermicide gel ) entire duration study Active malignancy history malignancy , exclude basal cell carcinoma skin excise prior study start History adverse reaction polyethylene glycol History severe multiple allergy Known Tuberculosis ( TB ) disease , high risk acquire TB infection , latent TB infection A history chronic infection , recent serious lifethreatening infection ( within 6 month , include herpes zoster ) , current sign symptom may indicate infection Subject history active systemic / respiratory infection due fungal , parasitic , mycotic pathogen include limited histoplasmosis , coccidiosis , paracoccidiosis , pneumocystis , blastomyces , aspergillus , nontuberculous mycobacteria History infect joint prosthesis time prosthesis still situ Positive hepatitis B surface antigen , hepatitis C Virus immunoglobulin G ( HCV IgG ) , Human Immunodeficiency Virus ( HIV ) test result Screening Subject blood pressure pulse rate ( measure supine position , 10 minute rest ) outside normal range A mean correct QT interval use Bazett 's formula ( QTcB ) interval &gt; 450 m Screening . If mean QTcB exceed limit , one additional triplicate electrocardiogram ( ECG ) may take . If triplicate also give abnormal result , subject exclude Any history evidence clinically significant ( CS ) cardiovascular , gastrointestinal , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy , CS abnormality , judge investigator History substance abuse , drug addiction alcoholism within 3 year prior Screening Inability abstain smoke inclinic stay Subject make blood donation comparable blood loss ( &gt; 350 mL ) within last 3 month prior first intake study drug Positive result alcohol test urine drug Screen Receiving Investigational Medicinal Product ( IMP ) within 3 month 5 halflives , whichever longer , prior first dose IMP schedule receive IMP CZP course study Previous exposure participate study antiTNFÎ± antibody ( Ab ) compound Use medication , prescription overthecounter within 14 day 5 halflives medication , whichever longer , first dose IMP , anticipate need medication study Has herb medication last 2 week prior screen , currently take Excessive use caffeinecontaining beverage exceed 500 mg caffeine/day ( 5 cup coffee )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Healthy Chinese subject</keyword>
</DOC>